Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

• मुख्य लेखकों: Shuwen Jiang (लेखक), Xiangkun Li (लेखक), Weifang Xue (लेखक), Sumei Xia (लेखक), Jian Wang (लेखक), Yang Sai (लेखक), Guangxiu Dai (लेखक), Weiguo Su (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively characterized in vitro and in vivo to support the f...